Nevro ROE 2013-2022 | NVRO

Current and historical return on equity (ROE) values for Nevro (NVRO) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Nevro ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-09-30 $-0.01B $0.33B -2.55%
2022-06-30 $-0.14B $0.23B -50.87%
2022-03-31 $-0.14B $0.24B -44.55%
2021-12-31 $-0.13B $0.30B -39.20%
2021-09-30 $-0.11B $0.32B -30.47%
2021-06-30 $-0.07B $0.36B -18.50%
2021-03-31 $-0.09B $0.37B -23.34%
2020-12-31 $-0.08B $0.39B -24.47%
2020-09-30 $-0.09B $0.38B -30.38%
2020-06-30 $-0.10B $0.37B -39.08%
2020-03-31 $-0.09B $0.22B -40.91%
2019-12-31 $-0.10B $0.22B -50.12%
2019-09-30 $-0.10B $0.20B -46.57%
2019-06-30 $-0.09B $0.20B -41.10%
2019-03-31 $-0.08B $0.21B -32.03%
2018-12-31 $-0.05B $0.25B -20.45%
2018-09-30 $-0.04B $0.24B -17.92%
2018-06-30 $-0.04B $0.25B -15.89%
2018-03-31 $-0.04B $0.24B -16.38%
2017-12-31 $-0.04B $0.25B -15.15%
2017-09-30 $-0.04B $0.24B -17.60%
2017-06-30 $-0.04B $0.24B -16.72%
2017-03-31 $-0.04B $0.24B -15.42%
2016-12-31 $-0.03B $0.25B -13.17%
2016-09-30 $-0.04B $0.25B -15.03%
2016-06-30 $-0.05B $0.25B -21.38%
2016-03-31 $-0.06B $0.23B -25.57%
2015-12-31 $-0.07B $0.24B -29.78%
2015-09-30 $-0.06B $0.24B -29.15%
2015-06-30 $-0.05B $0.26B -31.25%
2015-03-31 $-0.04B $0.16B -39.15%
2014-12-31 $-0.03B $0.17B -54.79%
2014-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.572B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $216.198B 22.61
Edwards Lifesciences (EW) United States $47.210B 32.49
Alcon (ALC) Switzerland $33.483B 28.83
STERIS (STE) Ireland $18.026B 22.43
Teleflex (TFX) United States $10.579B 17.16
Fresenius Medical Care AG KGaA (FMS) Germany $9.137B 9.17
Penumbra (PEN) United States $7.442B 1781.27
Globus Medical (GMED) United States $7.143B 36.31
Integer Holdings (ITGR) United States $2.386B 19.15
Glaukos (GKOS) United States $2.248B 0.00
Paragon 28 (FNA) United States $1.556B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.248B 17.77
Artivion (AORT) United States $0.525B 0.00